NAD+ IV therapy has moved from biohacker forums into mainstream wellness conversation, helped along by longevity podcasts and a growing number of clinic menus. It has also drawn skeptical coverage, including from NPR in May 2026. Both the enthusiasm and the skepticism have a point. Here is an honest accounting of what NAD+ is, what is established, and what is not.
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell. It is not a fringe supplement — it is foundational biochemistry, and it does two main jobs.
NAD+ levels decline with age. That observation is well established and is the entire foundation of the therapeutic interest.
The reasoning goes: NAD+ is essential, NAD+ declines with age, therefore restoring it should counteract aspects of aging. Patients typically seek it for energy, mental clarity, recovery, and general healthy-aging support.
The logic is coherent. Whether it holds up in humans is a separate question, and it is the question that matters.
Here is the honest answer: the foundational science is solid, and the human clinical evidence is early and incomplete.
What is well established is that NAD+ is essential to cellular metabolism, that its levels decline with age, and that severe deficiency of its precursor niacin causes pellagra, a serious disease. None of that is in dispute.
What is not established is that raising NAD+ levels in a healthy adult produces meaningful benefits in energy, cognition, or lifespan. Researchers consistently note that we remain in the early stages of human studies, and that the health benefits of augmenting NAD+ have not been demonstrated in large human trials. Much of the compelling data comes from cell cultures and animal models, which frequently fail to translate to people.
There is also a genuine open question about how NAD+ given intravenously is processed. NAD+ is a large molecule, and how much of an infusion reaches the inside of cells — where it would need to act — versus being broken down into precursors first is not fully resolved.
Many patients report feeling better. That is real and worth taking seriously, but subjective reports in an expensive, effortful, high-expectation treatment are also exactly the conditions under which placebo effects are strongest. Both things can be true simultaneously.
Sessions commonly run from around $200 to upwards of $1,000 depending on dose and location. Infusions are slow by necessity — often one to several hours — because infusing NAD+ quickly commonly produces chest tightness, nausea, flushing, or an uncomfortable sensation of pressure. Slowing the drip generally resolves these effects, which is why the infusion rate is titrated to comfort rather than run at a fixed speed.
This is a meaningful practical point. A rushed NAD+ infusion is an unpleasant one.
We would rather you make this decision with clear eyes than be sold on it.
A reasonable approach: treat NAD+ IV therapy as an optional, experimental addition — not a foundational intervention. Address sleep, resistance training, protein intake, and any diagnosable deficiency or hormonal issue first. Those have robust evidence and cost far less. If your fundamentals are genuinely handled, your labs are addressed, and you have discretionary budget and appropriate curiosity, NAD+ is a defensible thing to try with realistic expectations.
It is not a reasonable choice if it is substituting for a medical workup. Fatigue and brain fog are symptoms with a differential diagnosis — thyroid dysfunction, anemia, sleep apnea, depression, hormonal deficiency, and others. Several of those are common, checkable, and genuinely treatable. Buying an infusion to address undiagnosed fatigue can mean paying to postpone finding out what is actually wrong.
That is why we run labs first.
No. NAD+ infusions are not FDA-approved for treating aging, fatigue, or cognitive complaints. They are generally administered as a wellness service. This is an important distinction to understand before purchasing.
NAD+ infusions are generally well tolerated when administered slowly by trained clinicians in an appropriate setting. Infusing too quickly commonly causes chest tightness, nausea, and flushing. As with any IV therapy, there are risks associated with vascular access. Long-term safety data in healthy adults is limited, which is a consequence of how new the practice is.
IV administration bypasses digestion, which is the usual argument for it. Oral precursors such as nicotinamide riboside and nicotinamide mononucleotide have their own human trial literature, which is likewise mixed. There is no strong head-to-head evidence establishing that one route produces superior clinical outcomes.
There is no evidence-based standard protocol, because the outcome data needed to establish one does not yet exist. Any clinic presenting a precise schedule as clinically validated is overstating what is known.
There is no human evidence that NAD+ supplementation extends lifespan. Anyone claiming otherwise is going beyond the data.
We offer NAD+ therapy, and we would still rather rule out a treatable cause of your symptoms than sell you an infusion. Those are not in tension — the patients who do best with any wellness therapy are the ones whose actual medical picture has been sorted out first.
If you are curious about NAD+ or dealing with persistent fatigue and brain fog, call Alpine Health & Wellness in Kalispell, MT at 406-361-7421. Our provider team will start with functional wellness labs, tell you what they show, and give you a straight answer about whether NAD+ is worth your money.
This article is for general educational purposes and does not constitute medical advice. It does not establish a provider-patient relationship. NAD+ IV therapy is not FDA-approved for the treatment of any disease and is not appropriate for everyone. Statements regarding the state of the evidence reflect information available as of July 2026. Please consult a qualified healthcare provider about your individual circumstances.
